Go Pro
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel Free PACB Stock Alerts

Pacific Biosciences of California (PACB) Competitors

Pacific Biosciences of California logo
$1.50 +0.01 (+0.67%)
Closing price 04:00 PM Eastern
Extended Trading
$1.50 +0.00 (+0.33%)
As of 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

PACB vs. TXG, HBIO, LMNX, TMO, and WAT

Should you buy Pacific Biosciences of California stock or one of its competitors? MarketBeat compares Pacific Biosciences of California with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pacific Biosciences of California include 10x Genomics (TXG), Harvard Bioscience (HBIO), Defiance Daily Target 2X Long LMND ETF (LMNX), Thermo Fisher Scientific (TMO), and Waters (WAT).

How does Pacific Biosciences of California compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$642.82M9.04-$43.54M-$0.17N/A
Pacific Biosciences of California$160.01M2.91-$546.38M-$0.43N/A

10x Genomics currently has a consensus target price of $30.42, suggesting a potential downside of 33.57%. Pacific Biosciences of California has a consensus target price of $1.83, suggesting a potential upside of 22.22%. Given Pacific Biosciences of California's higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
1 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20
Pacific Biosciences of California
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

In the previous week, 10x Genomics had 6 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 10 mentions for 10x Genomics and 4 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 1.02 beat Pacific Biosciences of California's score of 0.41 indicating that 10x Genomics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
10x Genomics
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pacific Biosciences of California
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

10x Genomics has a net margin of -3.55% compared to Pacific Biosciences of California's net margin of -80.35%. 10x Genomics' return on equity of -2.86% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-3.55% -2.86% -2.23%
Pacific Biosciences of California -80.35%-571.06%-18.82%

84.7% of 10x Genomics shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

10x Genomics has a beta of 2.05, indicating that its stock price is 105% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market.

Summary

10x Genomics beats Pacific Biosciences of California on 13 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Harvard Bioscience?

Harvard Bioscience (NASDAQ:HBIO) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap life sciences tools & services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Harvard Bioscience presently has a consensus price target of $6.00, indicating a potential upside of 1.18%. Pacific Biosciences of California has a consensus price target of $1.83, indicating a potential upside of 22.22%. Given Pacific Biosciences of California's higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Harvard Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harvard Bioscience
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Pacific Biosciences of California
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

In the previous week, Pacific Biosciences of California had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 4 mentions for Pacific Biosciences of California and 2 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 1.23 beat Pacific Biosciences of California's score of 0.41 indicating that Harvard Bioscience is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harvard Bioscience
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pacific Biosciences of California
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Harvard Bioscience has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harvard Bioscience$86.55M0.31-$56.70M-$2.17N/A
Pacific Biosciences of California$160.01M2.91-$546.38M-$0.43N/A

Harvard Bioscience has a net margin of -11.44% compared to Pacific Biosciences of California's net margin of -80.35%. Harvard Bioscience's return on equity of -25.78% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
Harvard Bioscience-11.44% -25.78% -4.37%
Pacific Biosciences of California -80.35%-571.06%-18.82%

Harvard Bioscience has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market.

80.9% of Harvard Bioscience shares are held by institutional investors. 20.3% of Harvard Bioscience shares are held by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Harvard Bioscience beats Pacific Biosciences of California on 9 of the 15 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Defiance Daily Target 2X Long LMND ETF?

Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

In the previous week, Pacific Biosciences of California had 1 more articles in the media than Defiance Daily Target 2X Long LMND ETF. MarketBeat recorded 4 mentions for Pacific Biosciences of California and 3 mentions for Defiance Daily Target 2X Long LMND ETF. Defiance Daily Target 2X Long LMND ETF's average media sentiment score of 0.96 beat Pacific Biosciences of California's score of 0.41 indicating that Defiance Daily Target 2X Long LMND ETF is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Defiance Daily Target 2X Long LMND ETF
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pacific Biosciences of California
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Defiance Daily Target 2X Long LMND ETF has a beta of 9.31, indicating that its share price is 831% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market.

Defiance Daily Target 2X Long LMND ETF has a net margin of 5.39% compared to Pacific Biosciences of California's net margin of -80.35%. Defiance Daily Target 2X Long LMND ETF's return on equity of 4.66% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
Defiance Daily Target 2X Long LMND ETF5.39% 4.66% 2.91%
Pacific Biosciences of California -80.35%-571.06%-18.82%

Pacific Biosciences of California has a consensus target price of $1.83, indicating a potential upside of 22.22%. Given Pacific Biosciences of California's stronger consensus rating and higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Defiance Daily Target 2X Long LMND ETF.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Defiance Daily Target 2X Long LMND ETF
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Pacific Biosciences of California
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Defiance Daily Target 2X Long LMND ETF, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Defiance Daily Target 2X Long LMND ETF$437.66M0.01$15.17M$0.5135.88
Pacific Biosciences of California$160.01M2.91-$546.38M-$0.43N/A

87.8% of Defiance Daily Target 2X Long LMND ETF shares are held by institutional investors. 6.6% of Defiance Daily Target 2X Long LMND ETF shares are held by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Defiance Daily Target 2X Long LMND ETF beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and Pacific Biosciences of California (NASDAQ:PACB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Thermo Fisher Scientific has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$44.56B4.46$6.70B$18.1929.41
Pacific Biosciences of California$160.01M2.91-$546.38M-$0.43N/A

In the previous week, Thermo Fisher Scientific had 21 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 25 mentions for Thermo Fisher Scientific and 4 mentions for Pacific Biosciences of California. Thermo Fisher Scientific's average media sentiment score of 1.25 beat Pacific Biosciences of California's score of 0.41 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Thermo Fisher Scientific
21 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Pacific Biosciences of California
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Thermo Fisher Scientific presently has a consensus target price of $602.14, indicating a potential upside of 12.55%. Pacific Biosciences of California has a consensus target price of $1.83, indicating a potential upside of 22.22%. Given Pacific Biosciences of California's higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Thermo Fisher Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Thermo Fisher Scientific
0 Sell rating(s)
6 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.84
Pacific Biosciences of California
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

Thermo Fisher Scientific has a net margin of 15.15% compared to Pacific Biosciences of California's net margin of -80.35%. Thermo Fisher Scientific's return on equity of 16.86% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
Thermo Fisher Scientific15.15% 16.86% 8.15%
Pacific Biosciences of California -80.35%-571.06%-18.82%

Thermo Fisher Scientific has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market.

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Thermo Fisher Scientific beats Pacific Biosciences of California on 14 of the 17 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Waters?

Waters (NYSE:WAT) and Pacific Biosciences of California (NASDAQ:PACB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

94.0% of Waters shares are held by institutional investors. 0.3% of Waters shares are held by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Waters has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$3.17B11.69$642.63M$7.8747.88
Pacific Biosciences of California$160.01M2.91-$546.38M-$0.43N/A

In the previous week, Waters had 18 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 22 mentions for Waters and 4 mentions for Pacific Biosciences of California. Waters' average media sentiment score of 0.93 beat Pacific Biosciences of California's score of 0.41 indicating that Waters is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Waters
11 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pacific Biosciences of California
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Waters has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

Waters currently has a consensus price target of $401.60, suggesting a potential upside of 6.58%. Pacific Biosciences of California has a consensus price target of $1.83, suggesting a potential upside of 22.22%. Given Pacific Biosciences of California's higher possible upside, analysts plainly believe Pacific Biosciences of California is more favorable than Waters.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Waters
0 Sell rating(s)
9 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
2.73
Pacific Biosciences of California
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

Waters has a net margin of 11.91% compared to Pacific Biosciences of California's net margin of -80.35%. Waters' return on equity of 15.60% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
Waters11.91% 15.60% 8.90%
Pacific Biosciences of California -80.35%-571.06%-18.82%

Summary

Waters beats Pacific Biosciences of California on 14 of the 17 factors compared between the two stocks.

Get Pacific Biosciences of California News Delivered to You Automatically

Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PACB vs. The Competition

Export
MetricPacific Biosciences of CaliforniaMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$462.80M$7.66B$6.86B$12.45B
Dividend YieldN/A1.30%2.68%8.43%
P/E Ratio-3.4937.5022.2421.94
Price / Sales2.9175.24524.2593.49
Price / Cash1.8926.3148.5959.36
Price / Book75.007.0710.806.33
Net Income-$546.38M$162.30M$3.59B$331.02M
7 Day Performance-3.85%-2.46%-2.24%-1.09%
1 Month Performance14.50%-1.38%3.12%-0.49%
1 Year Performance2.74%3.26%26.30%19.90%

Pacific Biosciences of California Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PACB
Pacific Biosciences of California
2.2696 of 5 stars		$1.50
+0.7%		$1.83
+22.2%		+1.4%$462.80M$160.01MN/A730
TXG
10x Genomics
2.1737 of 5 stars		$40.00
+2.5%		$25.92
-35.2%		+226.3%$4.95B$642.82MN/A1,240
HBIO
Harvard Bioscience
1.0902 of 5 stars		$6.35
+3.3%		$6.00
-5.5%		+37.6%$27.74M$86.55MN/A490
LMNX
Defiance Daily Target 2X Long LMND ETF
N/A$23.57
+19.9%		N/AN/A$9.43M$437.66M46.221,325
TMO
Thermo Fisher Scientific
4.4564 of 5 stars		$517.76
-1.1%		$605.09
+16.9%		+21.5%$194.52B$44.56B28.46125,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PACB) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
How much money does your next trade really require?
If a stock trades at $300, most investors assume they need $300 per share. Sean Allison says that assumption m...
Trade Thirsty | Sponsoredtc pixel
Get the golden rules of day trading for free
Roger Scott spent over three decades trading through the dot-com bust, the financial crisis, the COVID crash, ...
The TradingPub | Sponsoredtc pixel
60 years. Zero competitors.
One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...
Behind the Markets | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel